Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

  1. Delforge, M.
  2. Terpos, E.
  3. Richardson, P.G.
  4. Shpilberg, O.
  5. Khuageva, N.K.
  6. Schlag, R.
  7. Dimopoulos, M.A.
  8. Kropff, M.
  9. Spicka, I.
  10. Petrucci, M.T.
  11. Samoilova, O.S.
  12. Mateos, M.-V.
  13. Magen-Nativ, H.
  14. Goldschmidt, H.
  15. Esseltine, D.-L.
  16. Ricci, D.S.
  17. Liu, K.
  18. Deraedt, W.
  19. Cakana, A.
  20. Van de Velde, H.
  21. San Miguel, J.F.
Aldizkaria:
European Journal of Haematology

ISSN: 0902-4441 1600-0609

Argitalpen urtea: 2011

Alea: 86

Zenbakia: 5

Orrialdeak: 372-384

Mota: Artikulua

DOI: 10.1111/J.1600-0609.2011.01599.X GOOGLE SCHOLAR